{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T17:52:00Z","timestamp":1778953920824,"version":"3.51.4"},"reference-count":63,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T00:00:00Z","timestamp":1755734400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100016197","name":"University of Toronto Leslie Dan Faculty of Pharmacy","doi-asserted-by":"publisher","award":["511794"],"award-info":[{"award-number":["511794"]}],"id":[{"id":"10.13039\/501100016197","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003579","name":"University of Toronto","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003579","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000032","name":"Institute of Infection and Immunity","doi-asserted-by":"publisher","award":["514798"],"award-info":[{"award-number":["514798"]}],"id":[{"id":"10.13039\/501100000032","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.dmd.2025.100152","type":"journal-article","created":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T23:17:39Z","timestamp":1756163859000},"page":"100152","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Severe acute respiratory syndrome coronavirus 2\u2013mediated dysregulation of drug processing genes is dependent on pathogenic variants, target site of infection, age, and sex"],"prefix":"10.1016","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1889-0334","authenticated-orcid":false,"given":"Chukwunonso K.","family":"Nwabufo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.dmd.2025.100152_bib1","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1002\/cpt.2698","article-title":"Impact of inflammation on midazolam metabolism in severe COVID-19 patients","volume":"112","author":"Le Carpentier","year":"2022","journal-title":"Clin Pharmacol Ther"},{"issue":"9","key":"10.1016\/j.dmd.2025.100152_bib2","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1093\/jac\/dkaa195","article-title":"Lopinavir pharmacokinetics in COVID-19 patients","volume":"75","author":"Gregoire","year":"2020","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"10.1016\/j.dmd.2025.100152_bib3","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.14193","article-title":"SARS-CoV-2 infection increases tacrolimus concentrations in solid-organ transplant recipients","volume":"35","author":"Salerno","year":"2021","journal-title":"Clin Transplant"},{"key":"10.1016\/j.dmd.2025.100152_bib4","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1124693","article-title":"SARS-CoV-2 infection dysregulates the expression of clinically relevant drug metabolizing enzymes in Vero E6 cells and membrane transporters in human lung tissues","volume":"14","author":"Nwabufo","year":"2023","journal-title":"Front Pharmacol"},{"issue":"9","key":"10.1016\/j.dmd.2025.100152_bib5","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1111\/bcp.16124","article-title":"COVID-19 severity gradient differentially dysregulates clinically relevant drug processing genes in nasopharyngeal swab samples","volume":"90","author":"Nwabufo","year":"2024","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.dmd.2025.100152_bib6","doi-asserted-by":"crossref","DOI":"10.1124\/dmd.124.001893","article-title":"Uncovering the impact of COVID-19-mediated bidirectional dysregulation of cytochrome P450 3A4 on systemic and pulmonary drug concentrations using physiologically based pharmacokinetic modeling","volume":"53","author":"Nwabufo","year":"2025","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"10.1016\/j.dmd.2025.100152_bib7","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.1071","article-title":"The influence of SARS-CoV-2 infection on expression of drug-metabolizing enzymes and transporters in a hACE2 murine model","volume":"11","author":"Deshpande","year":"2023","journal-title":"Pharmacol Res Perspect"},{"key":"10.1016\/j.dmd.2025.100152_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107627","article-title":"Inflammation is a major regulator of drug metabolizing enzymes and transporters: consequences for the personalization of drug treatment","volume":"215","author":"Stanke-Labesque","year":"2020","journal-title":"Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.dmd.2025.100152_bib9","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/s41440-023-01460-2","article-title":"The role of SARS-CoV-2-mediated NF-\u03baB activation in COVID-19 patients","volume":"47","author":"Zhou","year":"2024","journal-title":"Hypertens Res"},{"issue":"1","key":"10.1016\/j.dmd.2025.100152_bib10","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1038\/s41467-021-22713-z","article-title":"COVID-19 pathophysiology may be driven by an imbalance in the renin-angiotensin-aldosterone system","volume":"12","author":"Rysz","year":"2021","journal-title":"Nat Commun"},{"issue":"6","key":"10.1016\/j.dmd.2025.100152_bib11","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0252799","article-title":"Plasma ACE2 predicts outcome of COVID-19 in hospitalized patients","volume":"16","author":"Kragstrup","year":"2021","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.dmd.2025.100152_bib12","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1093\/procel\/pwae007","article-title":"Mutations in the SARS-CoV-2 spike receptor binding domain and their delicate balance between ACE2 affinity and antibody evasion","volume":"15","author":"Xue","year":"2024","journal-title":"Protein Cell"},{"issue":"7","key":"10.1016\/j.dmd.2025.100152_bib13","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.chom.2021.06.006","article-title":"SARS-CoV-2 spike L452R variant evades cellular immunity and increases infectivity","volume":"29","author":"Motozono","year":"2021","journal-title":"Cell Host Microbe"},{"issue":"1","key":"10.1016\/j.dmd.2025.100152_bib14","doi-asserted-by":"crossref","first-page":"e1128","DOI":"10.1093\/cid\/ciab721","article-title":"Clinical and virological features of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern: a retrospective cohort study comparing B.1.1.7 (Alpha), B.1.351 (Beta), and B.1.617.2 (Delta)","volume":"75","author":"Ong","year":"2022","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.dmd.2025.100152_bib15","doi-asserted-by":"crossref","first-page":"6013","DOI":"10.1038\/s41467-020-19808-4","article-title":"SARS-CoV-2 spike-protein D614G mutation increases virion spike density and infectivity","volume":"11","author":"Zhang","year":"2020","journal-title":"Nat Commun"},{"issue":"4","key":"10.1016\/j.dmd.2025.100152_bib16","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/s41591-021-01294-w","article-title":"Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies","volume":"27","author":"Chen","year":"2021","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.dmd.2025.100152_bib17","doi-asserted-by":"crossref","DOI":"10.4172\/2157-7609.1000119","article-title":"Sex differences in the expression of drug-metabolizing and transporter genes in human liver","volume":"3","author":"Yang","year":"2012","journal-title":"J Drug Metab Toxicol"},{"issue":"1","key":"10.1016\/j.dmd.2025.100152_bib18","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0245556","article-title":"Sex differences in susceptibility, severity, and outcomes of coronavirus disease 2019: cross-sectional analysis from a diverse US metropolitan area","volume":"16","author":"Vahidy","year":"2021","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.dmd.2025.100152_bib19","doi-asserted-by":"crossref","first-page":"6317","DOI":"10.1038\/s41467-020-19741-6","article-title":"Male sex identified by global COVID-19 meta-analysis as a risk factor for death and ITU admission","volume":"11","author":"Peckham","year":"2020","journal-title":"Nat Commun"},{"issue":"7837","key":"10.1016\/j.dmd.2025.100152_bib20","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/s41586-020-2700-3","article-title":"Sex differences in immune responses that underlie COVID-19 disease outcomes","volume":"588","author":"Takahashi","year":"2020","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.dmd.2025.100152_bib21","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1124\/dmd.124.001608","article-title":"Age-dependent changes in cytochrome P450 abundance and composition in human liver","volume":"52","author":"Subash","year":"2024","journal-title":"Drug Metab Dispos"},{"issue":"20","key":"10.1016\/j.dmd.2025.100152_bib22","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1001\/jama.2020.6775","article-title":"Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area","volume":"323","author":"Richardson","year":"2020","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.dmd.2025.100152_bib23","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00547-2020","article-title":"Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis","volume":"55","author":"Guan","year":"2020","journal-title":"Eur Respir J"},{"issue":"5","key":"10.1016\/j.dmd.2025.100152_bib24","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jinf.2020.03.004","article-title":"Clinical progression of patients with COVID-19 in Shanghai, China","volume":"80","author":"Chen","year":"2020","journal-title":"J Infect"},{"key":"10.1016\/j.dmd.2025.100152_bib25","series-title":"Emerging Variants of SARS-CoV-2 and Novel Therapeutics Against Coronavirus (COVID-19)","author":"Aleem","year":"2022"},{"issue":"1","key":"10.1016\/j.dmd.2025.100152_bib26","first-page":"1","article-title":"In vitro drug interaction studies \u2013 cytochrome P450 enzyme- and transporter-mediated drug interactions","volume":"1","year":"2020","journal-title":"FDA Guidance"},{"issue":"5","key":"10.1016\/j.dmd.2025.100152_bib27","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1080\/17425255.2021.1908262","article-title":"Drug metabolism in the lungs: opportunities for optimising inhaled medicines","volume":"17","author":"Enlo-Scott","year":"2021","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"6","key":"10.1016\/j.dmd.2025.100152_bib28","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1124\/molpharm.121.000333","article-title":"Remdesivir and EIDD-1931 interact with human equilibrative nucleoside transporters 1 and 2: implications for reaching SARS-CoV-2 viral sanctuary sites","volume":"100","author":"Miller","year":"2021","journal-title":"Mol Pharmacol"},{"issue":"28","key":"10.1016\/j.dmd.2025.100152_bib29","doi-asserted-by":"crossref","first-page":"16587","DOI":"10.1073\/pnas.2009799117","article-title":"Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development","volume":"117","author":"Imai","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7818","key":"10.1016\/j.dmd.2025.100152_bib30","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1038\/s41586-020-2342-5","article-title":"Pathogenesis and transmission of SARS-CoV-2 in golden hamsters","volume":"583","author":"Sia","year":"2020","journal-title":"Nature"},{"issue":"6520","key":"10.1016\/j.dmd.2025.100152_bib31","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1126\/science.abe2402","article-title":"REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters","volume":"370","author":"Baum","year":"2020","journal-title":"Science"},{"issue":"11","key":"10.1016\/j.dmd.2025.100152_bib32","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1038\/s41591-020-1070-6","article-title":"Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in hamsters","volume":"26","author":"Tostanoski","year":"2020","journal-title":"Nat Med"},{"issue":"11","key":"10.1016\/j.dmd.2025.100152_bib33","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.3390\/pharmaceutics12111002","article-title":"Development of remdesivir as a dry powder for inhalation by thin film freezing","volume":"12","author":"Sahakijpijarn","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.dmd.2025.100152_bib34","article-title":"In vivo pharmacokinetic study of remdesivir dry powder for inhalation in hamsters","volume":"3","author":"Sahakijpijarn","year":"2021","journal-title":"Int J Pharm X"},{"key":"10.1016\/j.dmd.2025.100152_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.120701","article-title":"Niclosamide inhalation powder made by thin-film freezing: multi-dose tolerability and exposure in rats and pharmacokinetics in hamsters","volume":"603","author":"Jara","year":"2021","journal-title":"Int J Pharm"},{"issue":"1","key":"10.1016\/j.dmd.2025.100152_bib36","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/s41467-022-28354-0","article-title":"The oral protease inhibitor (PF-07321332) protects Syrian hamsters against infection with SARS-CoV-2 variants of concern","volume":"13","author":"Abdelnabi","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.dmd.2025.100152_bib37","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.893635","article-title":"Pharmacokinetics, pharmacodynamics and antiviral efficacy of the MEK inhibitor zapnometinib in animal models and in humans","volume":"13","author":"Koch-Heier","year":"2022","journal-title":"Front Pharmacol"},{"issue":"4","key":"10.1016\/j.dmd.2025.100152_bib38","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00974-21","article-title":"Sex differences in lung imaging and SARS-CoV-2 antibody responses in a COVID-19 golden Syrian hamster model","volume":"12","author":"Dhakal","year":"2021","journal-title":"mBio"},{"issue":"7","key":"10.1016\/j.dmd.2025.100152_bib39","doi-asserted-by":"crossref","first-page":"779","DOI":"10.3390\/v12070779","article-title":"Age-dependent progression of SARS-CoV-2 infection in Syrian hamsters","volume":"12","author":"Osterrieder","year":"2020","journal-title":"Viruses"},{"issue":"6523","key":"10.1016\/j.dmd.2025.100152_bib41","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1126\/science.abe8499","article-title":"SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and transmission in vivo","volume":"370","author":"Hou","year":"2020","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.dmd.2025.100152_bib42","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.cell.2020.06.043","article-title":"Tracking changes in SARS-CoV-2 spike: evidence that D614G increases infectivity of the COVID-19 virus","volume":"182","author":"Korber","year":"2020","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.dmd.2025.100152_bib43","doi-asserted-by":"crossref","first-page":"5914","DOI":"10.1038\/s41467-023-40994-4","article-title":"Guadecitabine plus ipilimumab in unresectable melanoma: five-year follow-up and integrated multi-omic analysis in the phase 1b NIBIT-M4 trial","volume":"14","author":"Noviello","year":"2023","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.dmd.2025.100152_bib44","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s13073-023-01227-x","article-title":"SARS-CoV-2 infection induces a long-lived pro-inflammatory transcriptional profile","volume":"15","author":"Zhang","year":"2023","journal-title":"Genome Med"},{"issue":"1","key":"10.1016\/j.dmd.2025.100152_bib45","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1186\/1471-2105-6-225","article-title":"Pathway level analysis of gene expression using singular value decomposition","volume":"6","author":"Tomfohr","year":"2005","journal-title":"BMC Bioinformatics"},{"issue":"7","key":"10.1016\/j.dmd.2025.100152_bib46","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1038\/s41591-020-0968-3","article-title":"Extrapulmonary manifestations of COVID-19","volume":"26","author":"Gupta","year":"2020","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.dmd.2025.100152_bib47","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1004431","article-title":"Coordinating role of RXR\u03b1 in downregulating hepatic detoxification during inflammation revealed by fuzzy-logic modeling","volume":"12","author":"Keller","year":"2016","journal-title":"PLoS Comput Biol"},{"issue":"1","key":"10.1016\/j.dmd.2025.100152_bib48","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jfda.2018.11.005","article-title":"The regulation of drug-metabolizing enzymes and membrane transporters by inflammation: evidences in inflammatory diseases and age-related disorders","volume":"27","author":"Wu","year":"2019","journal-title":"J Food Drug Anal"},{"issue":"1","key":"10.1016\/j.dmd.2025.100152_bib49","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1186\/s12936-019-2860-5","article-title":"A non-lethal malarial infection results in reduced drug metabolizing enzyme expression and drug clearance in mice","volume":"18","author":"Mimche","year":"2019","journal-title":"Malar J"},{"issue":"4","key":"10.1016\/j.dmd.2025.100152_bib50","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1053\/jhep.2002.32102","article-title":"Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis","volume":"35","author":"Huang","year":"2002","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.dmd.2025.100152_bib51","first-page":"256","article-title":"Slow N-acetyltransferase 2 genotype affects the incidence of isoniazid and rifampicin-induced hepatotoxicity","volume":"4","author":"Ohno","year":"2000","journal-title":"Int J Tuberc Lung Dis"},{"issue":"6","key":"10.1016\/j.dmd.2025.100152_bib52","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.tube.2007.05.012","article-title":"Genetic polymorphisms of NAT2 and CYP2E1 associated with antituberculosis drug-induced hepatotoxicity in Korean patients with pulmonary tuberculosis","volume":"87","author":"Cho","year":"2007","journal-title":"Tuberculosis (Edinb)"},{"issue":"1","key":"10.1016\/j.dmd.2025.100152_bib53","doi-asserted-by":"crossref","first-page":"17","DOI":"10.2174\/157488611794479946","article-title":"Association of N-acetyltransferase-2 genotypes and anti-tuberculosis induced liver injury; first case-controlled study from Iran","volume":"6","author":"Khalili","year":"2011","journal-title":"Curr Drug Saf"},{"issue":"5","key":"10.1016\/j.dmd.2025.100152_bib54","first-page":"622","article-title":"NAT2 and CYP2E1 polymorphisms and susceptibility to first-line anti-tuberculosis drug-induced hepatitis","volume":"14","author":"Lee","year":"2010","journal-title":"Int J Tuberc Lung Dis"},{"issue":"1","key":"10.1016\/j.dmd.2025.100152_bib55","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s12072-011-9309-4","article-title":"Comparison between acetylator phenotype and genotype polymorphism of n-acetyltransferase-2 in tuberculosis patients","volume":"6","author":"Rana","year":"2012","journal-title":"Hepatol Int"},{"issue":"9","key":"10.1016\/j.dmd.2025.100152_bib56","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1164\/rccm.202101-0142LE","article-title":"ACE2 Elevation in Severe COVID-19","volume":"203","author":"Reindl-Schwaighofer","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.dmd.2025.100152_bib57","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1186\/s13054-020-03015-0","article-title":"Elevation of plasma angiotensin II level is a potential pathogenesis for the critically ill COVID-19 patients","volume":"24","author":"Wu","year":"2020","journal-title":"Crit Care"},{"key":"10.1016\/j.dmd.2025.100152_bib58","article-title":"Lethal COVID-19 associates with RAAS-induced inflammation for multiple organ damage including mediastinal lymph nodes","author":"Guarnieri","year":"2023","journal-title":"bioRxiv"},{"issue":"12","key":"10.1016\/j.dmd.2025.100152_bib59","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/j.tips.2022.09.005","article-title":"Pharmacokinetic considerations to optimize clinical outcomes for COVID-19 drugs","volume":"43","author":"Nwabufo","year":"2022","journal-title":"Trends Pharmacol Sci"},{"issue":"5","key":"10.1016\/j.dmd.2025.100152_bib60","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1021\/acscentsci.0c00489","article-title":"Remdesivir: a review of its discovery and development leading to emergency use authorization for treatment of COVID-19","volume":"6","author":"Eastman","year":"2020","journal-title":"ACS Cent Sci"},{"issue":"11","key":"10.1016\/j.dmd.2025.100152_bib61","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.7326\/ANNALS-24-00464","article-title":"National Institutes of Health COVID-19 treatment guidelines panel: perspectives and lessons learned","volume":"177","author":"Gulick","year":"2024","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.dmd.2025.100152_bib62","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1002\/cpt.2236","article-title":"Drugs in COVID-19 clinical trials: predicting transporter-mediated drug-drug interactions using in vitro assays and real-world data","volume":"110","author":"Yee","year":"2021","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.dmd.2025.100152_bib63","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s11481-025-10215-4","article-title":"COVID-19 alters inflammatory, mitochondrial, and protein clearance pathway genes: potential implications for new-onset parkinsonism in patients","volume":"20","author":"Nwabufo","year":"2025","journal-title":"J Neuroimmune Pharmacol"},{"issue":"2","key":"10.1016\/j.dmd.2025.100152_bib64","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s00280-023-04575-y","article-title":"Mirvetuximab soravtansine in ovarian cancer therapy: expert opinion on pharmacological considerations","volume":"93","author":"Nwabufo","year":"2024","journal-title":"Cancer Chemother Pharmacol"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955625091615?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955625091615?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T05:14:40Z","timestamp":1761714880000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955625091615"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":63,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S0090955625091615"],"URL":"https:\/\/doi.org\/10.1016\/j.dmd.2025.100152","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Severe acute respiratory syndrome coronavirus 2\u2013mediated dysregulation of drug processing genes is dependent on pathogenic variants, target site of infection, age, and sex","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dmd.2025.100152","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of American Society for Pharmacology and Experimental Therapeutics.","name":"copyright","label":"Copyright"}],"article-number":"100152"}}